High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. (Q53298016)

13 May 2018

title

High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. (English)

1 reference

13 May 2018

author name string

Michael H Roh

1

1 reference

13 May 2018

Yosuf Yassin

2

1 reference

13 May 2018

Alexander Miron

3

1 reference

13 May 2018

Karishma K Mehra

4

1 reference

13 May 2018

Mitra Mehrad

5

1 reference

13 May 2018

Nicolas M Monte

6

1 reference

13 May 2018

George L Mutter

7

1 reference

13 May 2018

Marisa R Nucci

8

1 reference

13 May 2018

Geng Ning

9

1 reference

13 May 2018

Frank D Mckeon

10

1 reference

13 May 2018

Michelle S Hirsch

11

1 reference

13 May 2018

Xian Wa

12

1 reference

13 May 2018

Christopher P Crum

13

1 reference

13 May 2018

publication date

18 June 2010

1 reference

13 May 2018

published in

Modern Pathology

1 reference

13 May 2018

volume

23

1 reference

13 May 2018

issue

10

1 reference

13 May 2018

page(s)

1316-1324

1 reference

13 May 2018

https://scigraph.springernature.com/pub.10.1038/modpathol.2010.119

exact match

0 references

cites work

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.119

beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.119

BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.119

A high frequency of sequence alterations is due to formalin fixation of archival specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.119

Germline mutations and polymorphisms in the origins of cancers in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.119

Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.119

7 January 2021

Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.119

7 January 2021

Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.119

7 January 2021

Precursors to pelvic serous carcinoma and their clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.119

7 January 2021

The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.119

7 January 2021

Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.119

7 January 2021

Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.119

7 January 2021

Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.119

7 January 2021

Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.119

7 January 2021

Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin?

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.119

7 January 2021

My approach to and thoughts on the typing of ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.119

7 January 2021

Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.119

7 January 2021

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.119

7 January 2021

PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.119

7 January 2021

PAX 2: a novel Müllerian marker for serous papillary carcinomas to differentiate from micropapillary breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.119

7 January 2021

Acquisition of a second mutation of the Tp53 alleles immediately precedes epithelial morphological transformation in ovarian tumorigenicity

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.119

7 January 2021

10.1038/MODPATHOL.2010.119

Identifiers

DOI

1 reference

13 May 2018

PubMed ID

20562848

1 reference

13 May 2018